Sign In
Buy HALO
$76.20
-2.42 (-3.08%)
At Close: Jul 10, 2026
Time to Buy Wide Moat & HALO ETFs?
12:00pm, Friday, 10'th Jul 2026
Wall Street is caught in the midst of shifting geopolitical stances of the United States and Iran, chances of higher global inflation, weak U.S. jobs data, the possibility of stagflation in the U.S. e
Halozyme Appoints David Ramsay as President Drug Delivery
04:02pm, Tuesday, 30'th Jun 2026
SAN DIEGO, June 30, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced the appointment of David Ramsay as President Drug Delivery, effective
SAN DIEGO, June 15, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today confirmed that the Company expects zero to minimal royalty revenue impact based
Halozyme Therapeutics (HALO) Up 0.8% Since Last Earnings Report: Can It Continue?
12:31pm, Wednesday, 10'th Jun 2026
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock?
Anti-AI Investing: The HALO Moat Goes Off The Rails
08:02am, Tuesday, 09'th Jun 2026
North American railroads like UNP, NSC, CSX, CNI, and CP exhibit HALO traits: irreplaceable heavy assets, low obsolescence, and durable cash flows. Current railroad valuations are rich, with multiples
Sky Harbour: The Ultimate HALO Investment Taking Flight
08:00am, Sunday, 07'th Jun 2026
Sky Harbour is building a national network of private aviation campuses on some of America's most irreplaceable airport real estate. The company's business model fits squarely within my HALO framework
Anti-AI Investing: The HALO Moat
08:00am, Sunday, 31'st May 2026
I focus on HALO investing: Heavy Assets, Low Obsolescence - owning irreplaceable physical assets with durable moats against technological disruption. Top recommendations include American Tower, Brookf
Implied Volatility Surging for Halozyme Therapeutics Stock Options
10:31am, Tuesday, 26'th May 2026
Investors need to pay close attention to HALO stock based on the movements in the options market lately.
Halozyme Therapeutics: Royalty King
10:33pm, Tuesday, 19'th May 2026
Halozyme Therapeutics is delivering strong shareholder value, driven by robust royalty growth and disciplined capital allocation. HALO posted a double beat on Q1 2026 earnings, reaffirmed 2026–2028
Acquisition gives Nexalin control of AI-integrated remote patient-monitoring, clinical data-capture and virtual-care infrastructure already deployed at UCSD Acquisition gives Nexalin control of AI-int
One of the market's hottest stock themes is buying everything AI can't replace
10:21am, Sunday, 17'th May 2026
Josh Brown, co-founder and CEO of Ritholtz Wealth Management, coined the term HALO as a way to identify companies immune to AI disruption. Many HALO stocks are outperforming this year, such as FedEx,
Roundhill launches "HALO" ETF
04:51pm, Thursday, 14'th May 2026
Dave Mazza, CEO of Roundhill Investments, joins CNBC's "Halftime Report" to highlight the launch of their new "HALO" ETF coined by our very own Josh Brown. It stands for "Heavy Assets, Low Obsolescenc
Halozyme's Q1 Earnings & Revenues Beat Estimates, Stock Up
12:51pm, Tuesday, 12'th May 2026
HALO beats Q1 earnings estimates as royalty revenues from partner drugs and strong product sales lift revenues by 42% year over year.
Halozyme Therapeutics, Inc. (HALO) Q1 2026 Earnings Call Transcript
10:50pm, Monday, 11'th May 2026
Halozyme Therapeutics, Inc. (HALO) Q1 2026 Earnings Call Transcript
Halozyme Therapeutics Q1 Earnings Call Highlights
08:09pm, Monday, 11'th May 2026
Halozyme Therapeutics NASDAQ: HALO reported a sharp increase in first-quarter 2026 revenue and earnings, driven by continued growth in royalties from its ENHANZE drug-delivery platform, and announced
